Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
出版年份 2015 全文链接
标题
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
作者
关键词
Pancreatic ductal adenocarcinoma, Advanced pancreatic cancer, Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Novel therapies, Biomarkers
出版物
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-05-02
DOI
10.1186/s13045-015-0141-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
- (2014) K. H. Yu et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
- (2014) Xun Yuan et al. Journal of Hematology & Oncology
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
- (2013) B. M. Wolpin et al. ANNALS OF ONCOLOGY
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice
- (2013) Bincy Philip et al. GASTROENTEROLOGY
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- Therapeutic Advances in Pancreatic Cancer
- (2013) Andrew Scott Paulson et al. GASTROENTEROLOGY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
- (2013) Brian A. Boone et al. JOURNAL OF SURGICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution and dynamics of pancreatic cancer progression
- (2013) S Yachida et al. ONCOGENE
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
- (2013) J. E. Faris et al. ONCOLOGIST
- Metformin and Survival in Pancreatic Cancer
- (2013) Allen L. Hwang et al. PANCREAS
- Risk Factors and Therapeutic Targets in Pancreatic Cancer
- (2013) Sonja Maria Wörmann et al. Frontiers in Oncology
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
- (2012) Peter J Hosein et al. BMC CANCER
- Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma
- (2012) Hao Xie et al. CANCER
- Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer
- (2012) Allyson J. Ocean et al. CANCER
- Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
- (2012) Masato Ozaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
- (2012) N. Sadeghi et al. CLINICAL CANCER RESEARCH
- Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
- (2012) Jiujie Cui et al. CURRENT PHARMACEUTICAL DESIGN
- T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
- (2012) Markus Chmielewski et al. GASTROENTEROLOGY
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
- (2012) Marcia Irene Canto et al. GUT
- Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
- (2012) Jeffrey M. Hardacre et al. JOURNAL OF GASTROINTESTINAL SURGERY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- (2012) Krishna S. Gunturu et al. MEDICAL ONCOLOGY
- The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
- (2012) M. Mizuma et al. MOLECULAR CANCER THERAPEUTICS
- An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer
- (2012) Andrew D. Gilliam et al. PANCREAS
- TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation
- (2012) Jonas Fuxe et al. SEMINARS IN CANCER BIOLOGY
- Adamantyl Retinoid-Related Molecules Induce Apoptosis in Pancreatic Cancer Cells by Inhibiting IGF-1R and Wnt/β-Catenin Pathways
- (2012) Lulu Farhana et al. Journal of Oncology
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
- (2011) William F. Regine et al. ANNALS OF SURGICAL ONCOLOGY
- Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer
- (2011) Jayme B. Stokes et al. ANNALS OF SURGICAL ONCOLOGY
- A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
- (2011) Yefei Rong et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- Pancreatic cancer risk and levels of trace elements
- (2011) André F S Amaral et al. GUT
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer
- (2011) Manish Patel et al. JOURNAL OF SURGICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Tumor: Stroma interactions in pancreatic pancer: Will this sparc prove a raging fire?
- (2010) Keith A Cengel et al. CANCER BIOLOGY & THERAPY
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Alcohol Intake and Pancreatic Cancer Risk: A Pooled Analysis of Fourteen Cohort Studies
- (2009) J. M. Genkinger et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
- (2009) A. Blackford et al. CANCER RESEARCH
- Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
- (2009) K. Kisfalvi et al. CANCER RESEARCH
- Antidiabetic Therapies Affect Risk of Pancreatic Cancer
- (2009) Donghui Li et al. GASTROENTEROLOGY
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
- (2009) H. Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pancreatic Cancer
- (2008) Anirban Maitra et al. Annual Review of Pathology-Mechanisms of Disease
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)
- (2008) A. Maeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Gauri R. Varadhachary et al. JOURNAL OF CLINICAL ONCOLOGY
- Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial
- (2008) William Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started